<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785183</url>
  </required_header>
  <id_info>
    <org_study_id>42/18 - 2018</org_study_id>
    <nct_id>NCT04785183</nct_id>
  </id_info>
  <brief_title>Antioxidant Effects of Melatonin in Preterm</brief_title>
  <official_title>Early Supplementation of Melatonin in Preterm Newborns: the Effects on Oxidative Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Policlinico &quot;G. Martino&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Policlinico &quot;G. Martino&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm infants are at risk of free radical mediated diseases from oxidative stress (OS)&#xD;
      injury. Melatonin (MEL) is a powerful antioxidant and scavenger of free radicals. In preterm&#xD;
      neonates, melatonin deficiency has been reported. Several studies tested the efficacy of&#xD;
      melatonin to counteract oxidative damage in diseases of newborns such as chronic lung&#xD;
      disease, perinatal brain injury, necrotizing enterocolitis, retinopathy of prematurity and&#xD;
      sepsis, giving promising results. In these studies, the dosages of melatonin varied over a&#xD;
      wide range. The present study was designed to test the hypothesis that oral administration of&#xD;
      melatonin reduced OS and consequentially, the occurrence of intraventricular haemorrhage&#xD;
      (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) and bronchopulmonary&#xD;
      dysplasia (BPD) in preterm newborns.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the melatonin concentration</measure>
    <time_frame>All participants will be evaluated at 24 hours of life</time_frame>
    <description>Analysis of melatonin concentration in treated group (MEL group) and controls (placebo group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the melatonin concentration</measure>
    <time_frame>All participants will be evaluated at 48 hours of life</time_frame>
    <description>Analysis of melatonin concentration in treated group (MEL group) and controls (placebo group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of AOPP</measure>
    <time_frame>All participants will be evaluated at 24 hours of life</time_frame>
    <description>Evaluation of advanced oxidative protein products (AOPP) in treated group (MEL group) and controls (placebo group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of NPBI</measure>
    <time_frame>All participants will be evaluated at 24 hours of life</time_frame>
    <description>Evaluation of non protein binding iron (NPBI) in treated group (MEL group) and controls (placebo group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of isoprostanes</measure>
    <time_frame>All participants will be evaluated at 24 hours of life</time_frame>
    <description>Evaluation of isoprostanes in treated group (MEL group) and controls (placebo group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of AOPP</measure>
    <time_frame>All participants will be evaluated at 48 hours of life</time_frame>
    <description>Evaluation of advanced oxidative protein products (AOPP) in treated group (MEL group) and controls (placebo group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of NPBI</measure>
    <time_frame>All participants will be evaluated at 48 hours of life</time_frame>
    <description>Evaluation of non protein binding iron (NPBI) in treated group (MEL group) and controls (placebo group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of isoprostanes</measure>
    <time_frame>All participants will be evaluated at 48 hours of life</time_frame>
    <description>Evaluation of isoprostanes in treated group (MEL group) and controls (placebo group)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of the free radical diseases of prematurity occurence</measure>
    <time_frame>At 3 months of life</time_frame>
    <description>Evaluation of the occurrence of intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) and bronchopulmonary dysplasia (BPD)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Newborn Morbidity</condition>
  <condition>Oxidative Stress</condition>
  <condition>Pre-Term</condition>
  <condition>Melatonin Deficiency</condition>
  <arm_group>
    <arm_group_label>Melatonin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin drops</intervention_name>
    <description>Melatonin oral administration</description>
    <arm_group_label>Melatonin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral 5% glucose</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age &lt;37 weeks&#xD;
&#xD;
          -  Normal liver function tests&#xD;
&#xD;
          -  Normal kidney function tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All babies not born in the clinic&#xD;
&#xD;
          -  All babies with severe congenital malformations&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Inborn errors of metabolism&#xD;
&#xD;
          -  Babies suffering from perinatal asphyxia&#xD;
&#xD;
          -  Babies born from mothers with mental disorders&#xD;
&#xD;
          -  Sample hemolysis&#xD;
&#xD;
          -  Insufficient sample&#xD;
&#xD;
          -  withdraw informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eloisa Gitto</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

